Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 30:7:F1000 Faculty Rev-1159.
doi: 10.12688/f1000research.14991.1. eCollection 2018.

Recent advances in the molecular epidemiology of clinical malaria

Mario Recker  1 , Peter C Bull  2 , Caroline O Buckee  3
Affiliations
Review

Recent advances in the molecular epidemiology of clinical malaria

Mario Recker et al. F1000Res. .

Abstract

Human malaria is a complex disease that can show a wide array of clinical outcomes, from asymptomatic carriage and chronic infection to acute disease presenting various life-threatening pathologies. The specific outcome of an infection is believed to be determined by a multifactorial interplay between the host and the parasite but with a general trend toward disease attenuation with increasing prior exposure. Therefore, the main burden of malaria in a population can be understood as a function of transmission intensity, which itself is intricately linked to the prevalence of infected hosts and mosquito vectors, the distribution of infection outcomes, and the parasite population diversity. Predicting the long-term impact of malaria intervention measures therefore requires an in-depth understanding of how the parasite causes disease, how this relates to previous exposures, and how different infection pathologies contribute to parasite transmission. Here, we provide a brief overview of recent advances in the molecular epidemiology of clinical malaria and how these might prove to be influential in our fight against this important disease.

Keywords: epidemiology; infectivity; malaria; natural acquired immunity; severe disease.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. WHO Malaria Report: World malaria report 2017.2017. Reference Source
    1. Olotu A, Fegan G, Wambua J, et al. : Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med. 2016;374(26):2519–29. 10.1056/NEJMoa1515257 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Bhatt S, Weiss DJ, Cameron E, et al. : The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207–11. 10.1038/nature15535 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Snow RW, Sartorius B, Kyalo D, et al. : The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900. Nature. 2017;550(7677):515–8. 10.1038/nature24059 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Nkumama IN, O'Meara WP, Osier FHA: Changes in Malaria Epidemiology in Africa and New Challenges for Elimination. Trends Parasitol. 2017;33(2):128–40. 10.1016/j.pt.2016.11.006 - DOI - PMC - PubMed

    2. F1000 Recommendation

Publication types